Loading organizations...
MoldCo is a healthcare technology company providing a patented protocol for recovering from mold toxicity. The company delivers telehealth services, comprehensive lab testing, and a structured three-step recovery plan: Detox, Clear, and Repair, all facilitated by board-certified medical providers and built upon decades of research.
Ariana Thacker founded MoldCo around 2022, driven by her personal struggle with a mold-related illness. This experience fueled her mission to create an accessible solution, drawing heavily upon the pioneering clinical insights and extensive research of Dr. Ritchie Shoemaker, a recognized authority in chronic inflammatory response syndrome.
The company serves individuals suffering from mold-related illnesses who often face misdiagnosis and limited treatment options. MoldCo's vision is to make effective mold recovery solutions widely accessible and to advance the scientific understanding and treatment of mold toxicity through ongoing research and increased awareness.
MoldCo has raised $11.0M across 2 funding rounds.
MoldCo has raised $11.0M in total across 2 funding rounds.
MoldCo has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $8M Seed | Collaborative Fund, Amee Kapadia | Andrew Montgomery, Starship Ventures, Trammell Venture Partners, Stephen Cole | Announced |
| Dec 1, 2024 | $3M Seed | — | Andrew Montgomery, Forerunner Ventures, Long Journey Ventures, Pareto Holdings, Seaside Ventures, Starship Ventures, Trammell Venture Partners, Visible Ventures, Winklevoss Capital, Balaji Srinivasan, Evan Moore, Logan Paul, Marc Baghadjian, Scott Banister, Stephen Cole, Steve Aoki, Ariana Thacker, Behind Genius Ventures, Bleu Capital, Boost VC, Moth Fund, Night Ventures, SALT | Announced |
MoldCo is a clinician-led digital health platform that standardizes mold detox as routine preventative care, offering telehealth consultations, advanced lab testing for mold toxicity biomarkers, evidence-based treatments like binders and peptides, and home-delivered care for symptoms such as fatigue, brain fog, and chronic inflammation.[1][2][4][6] It serves patients nationwide via telehealth in states like California, Florida, Massachusetts, Michigan, Ohio, and Texas, with lab testing in 45 states, targeting the overlooked crisis of Mold Toxicity and Chronic Inflammatory Response Syndrome (CIRS).[1][2] Backed by $8M in seed funding and leading VCs, physicians, and researchers, MoldCo demonstrates strong growth momentum through expansions like its 2025 California launch and partnership with Monarch Athletic Club for exclusive member discounts.[1][5]
MoldCo was founded by Ariana Thacker, its CEO, who launched the company to address the "invisible health crisis" of mold-related illnesses dismissed by conventional medicine, drawing on 30+ years of research by pioneers like Dr. Ritchie Shoemaker, MoldCo's Founding Physician.[1][3] Thacker's vision emerged from recognizing gaps in accessible, evidence-based mold detox care, leading to a clinician-led model with input from world-renowned physicians and researchers in environmental medicine.[1][3] Early traction includes nationwide lab availability by 2025, state expansions, high-profile partnerships like Monarch Athletic Club, and $8M seed funding to scale its virtual clinic.[1][5] Key figures like Medical Director Dr. Scott McMahon, who built a practice helping thousands with mold illness, and Dr. Shoemaker's peer-reviewed protocols underpin its rapid evolution toward full U.S. coverage by 2026.[1][3]
MoldCo rides the wave of telehealth expansion and rising awareness of environmental health crises, where mold toxicity affects millions but is often misdiagnosed amid growing demand for personalized, home-based care post-pandemic.[1][2] Its timing aligns with market forces like increased focus on preventative wellness, air quality concerns, and biotech advances in biomarkers, filling gaps in conventional medicine that overlooks CIRS symptoms.[2][3] By partnering with wellness clubs and securing VC funding, MoldCo influences the ecosystem, pioneering scalable models for toxin-related illnesses and potentially templating platforms for air pollution or chemical exposures.[1][2][5]
MoldCo is poised for nationwide rollout by 2026, scaling its virtual clinic with ongoing research into precision treatments and biomarkers to dominate mold detox as standard care.[1][3] Trends like AI-driven diagnostics, expanded telehealth regulations, and consumer wellness booms will accelerate growth, evolving its influence from niche disruptor to ecosystem shaper in environmental health tech. As the first mover standardizing this overlooked crisis, MoldCo redefines preventative care for millions feeling dismissed—proving recovery from mold toxicity is accessible and routine.[1][2]
MoldCo has raised $11.0M in total across 2 funding rounds.
MoldCo's investors include Collaborative Fund, Amee Kapadia, Andrew Montgomery, Starship Ventures, Trammell Venture Partners, Stephen Cole, Forerunner Ventures, Long Journey Ventures, Pareto Holdings, Seaside Ventures, Visible Ventures, Winklevoss Capital.
